Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06554288 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy

Study acronym: TRIKE2
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints: 10 to 12
    • Site contact updated
    v6
  2. Primary completion date: Sep 30, 2026 to Nov 30, 2029
    • Study completion date: Oct 31, 2026 to Dec 31, 2029
    • Site contact updated
    v5
  3. Re-verified, no change to tracked fieldsv4
  4. Start date: Sep 30, 2024 to Oct 15, 2024v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date: Sep 15, 2024 to Sep 30, 2024
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this is impacted by a person's genetics. Information from this study will also be used to design future clinical trials.
Trial Details
NCT Number NCT06554288
Lead Sponsor Children's Mercy Hospital Kansas City
Collaborators: University of Kansas Medical Center
Conditions
(from sponsor)		 Pediatric Disorder, Genetic Predisposition, Dystonia, Secondary, Dystonia, Cerebral Palsy, Dystonic-Rigid, Cerebral Palsy, Dyskinetic, Trihexyphenidyl Adverse Reaction, Pharmacogenomic Drug Interaction
Related terms Cerebral Palsy, Dystonia, Dystonic Disorders, Genetic Predisposition to Disease
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov